HIV news from FiercePharma
NewsDocs back Viread for hepatitis B
Analysts are chatting up Gilead Science's HIV drug Viread as a treatment for hepatitis B. Currently under FDA review for that indication, Viread already has the backing of four out of five doctors, Read more...
Did GSK ignore early abacavir warning?
Back in 2005, Swedish pharma monitors raised a red flag on the HIV fighter abacavir and its possible link to heart attacks, The Independent is reporting. Thirty-four patients taking abacavir had Read more...
Brazil mulls patent-busting on Tenofovir
The Brazilian government recently deemed the anti-HIV med Tenofovir a "public interest." That's code for, "We're thinking about issuing a compulsory license for this drug." Under Read more...
GSK tests sliding-scale prices
Is sliding scale the way to go in emerging markets? GlaxoSmithKline wanted to know. So the company is testing a radical new pricing plan that would offer meds to patients according to their ability Read more...
Three-way HIV combo approved in EU
Call it a trifecta. European regulators have approved Atripla, the combination HIV med that allows patients to get their entire drug cocktail in just one pill a day. The approval is another coup for Read more...
Pfizer nets first AIDS patent in India
Pfizer cleared a big milestone in India today: The company became the first to get patent protection for an AIDS drug there. The new patent covers Celzentry, or maraviroc, a new, first-in-class HIV Read more...
Who tainted Roche's Viracept?
A new regulatory report gives us a peek at the recall of Roche's HIV remedy Viracept--and it's not a pretty picture. You'll remember that Viracept was withdrawn from the European market in June Read more...
ALSO NOTED: Caraco gets FDA nod for GSK seizure drug; Mylan prices offering of stock;
> Caraco Pharmaceutical got tentative FDA approval for its copycat form of GlaxoSmithKline's Lamictal, a remedy for seizures and bipolar episodes that sold some $1.89 billion in the 12 months Read more...
ALSO NOTED: GSK to launch cervical cancer vaccine in EU;Ranbaxy licenses Sirtex cancer remedy;
> GlaxoSmithKline is now ready to launch its vaccine against cervical cancer, Cervarix, in the E.U--and analysts expect revenues of $2 billion to $5 billion there, based on rival Gardisil's Read more...
SPOTLIGHT: Adcock Ingram gets free license for Merck HIV remedy
South African generics maker Adcock Ingram nabbed a royalty-free license from Merck on its anti-HIV drug Stocrin (efavirenz). The South African government has been buying the brand-name drug from Read more...
| Press ReleasesPRESS RELEASE: MSD grants Adcock Ingram a license to manufacture and supply efavirenz MSD grants Adcock Ingram a license to manufacture and supply efavirenz, an antiretroviral medicine for the treatment of HIV infection Merck & Co., Inc., Whitehouse Station, New Jersey (which Read more... PRESS RELEASE: Presidio Pharmaceuticals Closes $26 Million Series B Financing Presidio Pharmaceuticals Closes $26 Million Series B Financing SAN FRANCISCO -- Presidio Pharmaceuticals, Inc, a specialty pharmaceutical company focused on developing and commercializing novel, Read more... |
Get more HIV coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends